^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Apoptosis inducer

    Related drugs:
    11d
    Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=75, Recruiting, Oncorena AB | Trial completion date: Aug 2025 --> May 2027 | Trial primary completion date: Feb 2025 --> May 2027 | N=50 --> 75
    Enrollment change • Trial completion date • Trial primary completion date
    1m
    Multi-omics profiling of ACOX3 unveils pan-cancer clinical biomarker potential. (PubMed, Comput Biol Chem)
    ACOX3 represents a dual diagnostic and prognostic biomarker with broad pan-cancer relevance, exhibiting distinct immune correlates and therapeutic potential.
    Journal • Pan tumor
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    AZD6482 • TGX-221
    2ms
    Evaluation of BH4 Responsiveness in Our PKU Patients (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Sohag University
    New P1 trial
    2ms
    Chemoresistance mitigation of dual drug-loaded nanoparticles with doxorubicin and curcumin. (PubMed, Cytotechnology)
    This study investigates the characterization and biological effects of Dual Drug-Loaded Nanoparticles on HepG2/doxorubicin (DOX) cells, focusing on the anti-cancer ability of Doxorubicin/Curcumin-Polyethylene Glycol-Polycaprolactone Nanoparticles (DOX/Cur-PEG-PCL-NPs)...These results demonstrate that DOX/Cur-PEG-PCL-NPs effectively reverse chemoresistance and suppress tumor progression through modulation of the Nrf2 pathway and apoptosis induction, offering a promising strategy for targeted liver cancer therapy. The online version contains supplementary material available at 10.1007/s10616-025-00855-y.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCC1 (ATP Binding Cassette Subfamily C Member 1) • HMOX1 (Heme Oxygenase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • NQO1 (NAD(P)H dehydrogenase, quinone 1)
    |
    curcumin/doxorubicin (iMX-110)
    2ms
    Pan-cancer multi-omics analysis reveals IQCE as a malignant cell-restricted oncogenic biomarker driving immunosuppression and chemoresistance in cutaneous melanoma. (PubMed, Discov Oncol)
    IQCE emerges as a novel oncogene-associated biomarker with significant diagnostic and prognostic utility, particularly in SKCM. It promotes an immunosuppressive TME and oncogenic signaling while being localized to malignant cells. Although associated with chemoresistance, the vulnerability of IQCE-high tumors to RITA offers a promising therapeutic strategy. IQCE represents a compelling target for precision oncology.
    Journal • Pan tumor
    |
    TP53 (Tumor protein P53)
    |
    RITA
    4ms
    KNAN2001: Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=12, Enrolling by invitation, Keystone Nano, Inc | Not yet recruiting --> Enrolling by invitation | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Jul 2026 --> Feb 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Ceraxa (nanoliposomal ceramide)
    4ms
    XON9-A Glyco-Humanized Polyclonal Antibody Effective Against Hepatocellular Carcinoma. (PubMed, Int J Mol Sci)
    Treatments for advanced HCC include multikinase inhibitors (Sorafenib or Lenvatinib), with limited response rates and serious side effects, or immunotherapy applicable to a small fraction of patients. No toxicity was observed after repeated injections of XON9 in a non-human primate. XON9 represents a promising and selective immunotherapy against refractory HCC.
    Journal
    |
    CASP8 (Caspase 8) • CASP9 (Caspase 9)
    |
    sorafenib • Lenvima (lenvatinib)
    4ms
    ST-001-010: Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=46, Recruiting, SciTech Development, Inc. | Trial completion date: Nov 2025 --> May 2027 | Trial primary completion date: May 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    fenretinide nanoparticle (ST-001 nanoFenretinide)
    4ms
    NK cell-related genes-driven novel molecular subtyping and prognostic signatures for Wilms tumor: uncovering the therapeutic potential of TGX-221 and biomarker role of HS2ST1. (PubMed, Front Oncol)
    Moreover, TGX-221 represents a promising novel therapeutic candidate, while HS2ST1 serves as a potential prognostic biomarker. These findings collectively provide tools for risk stratification and targeted therapy, advancing precision oncology for WT.
    Journal
    |
    PPP3CA (Protein Phosphatase 3 Catalytic Subunit Alpha)
    |
    TGX-221
    6ms
    Exercise and NO in HFrEF (clinicaltrials.gov)
    P1, N=68, Completed, VA Office of Research and Development | Recruiting --> Completed | N=140 --> 68 | Trial completion date: May 2026 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date
    6ms
    Novel anticancer inhibitors targeting the PI3K/Akt/mTOR signaling route and apoptosis inducers: A study on the apoptosis mechanism via the intrinsic mitochondrial-mediated pathway. (PubMed, Chem Biol Interact)
    Moreover, 6i demonstrated a promising safety profile in hERG assay. Taken together, our finding suggest that 6i may be a potential candidate for further in vivo investigation.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9)
    8ms
    KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P1/2, N=148, Suspended, Primocure Pharma | Trial completion date: Nov 2025 --> Nov 2027 | Active, not recruiting --> Suspended | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial completion date • Trial suspension • Trial primary completion date